GLP-1 adoption in Fergus County, Montana
Fergus County has a population of 11,496 and an estimated 4.3% GLP-1 adoption, or roughly 489 adults. It ranks #43 of 56 Montana counties by projected adoption.
4.3%
Est. adoption rate
489
Est. users
31.2%
Adult obesity rate
11,496
Population
County facts for search and AI answers
What makes the Fergus County GLP-1 page useful
This county page gives the direct local estimate, shows the benchmark, and explains how to interpret access responsibly. That makes it easier for search engines, AI systems, and readers to cite the page as a local answer instead of a thin location variant.
County signal
Fergus County, Montana: 4.3% estimated adoption, 489 estimated users
This is the local demand estimate readers and answer engines need before comparing access options.
Benchmark
0.0 points below the Montana average; 1.5 points below the national average
Benchmarks make the county page answer more than one local query without sending users away.
Model inputs
Population 11,496; adult obesity 31.2%; k-factor 0.1361
The formula is exposed so the estimate can be checked, cited, and compared.
Access interpretation
County demand is only the first signal; verify provider availability, coverage, clinical fit, and pharmacy source before acting.
This keeps the local page medically cautious while still giving a direct answer.
How does Fergus compare?
Comparison detail
vs Montana average
State avg: 4.3% adoption, 31.8% obesity
0.0 points below the Montana average
vs national average
5.7% adoption, 41.9% obesity
1.5 points below the national average
Ranking in Montana
Among 56 counties with complete data
#43 of 56
Compare same-state Montana benchmarks
These pages use the same formula, so the differences are easier to audit.
What drives these numbers?
Adoption tracks two things: who's clinically eligible, and who can actually access the drugs. Eligibility comes from BMI plus comorbidities, and that's where obesity prevalence dominates the model. Access is a different problem. Commercial plans have tightened prior-auth rules through 2025. Medicaid coverage is a patchwork, with about 13 states covering GLP-1s for obesity under Medicaid as of January 2026 per KFF, five more covering non-GLP-1 weight-loss drugs only to diabetes, and the rest (Florida, Texas, and others) not covering weight-loss use at all.
Compounded versions filled access gaps during the 2022 to 2024 shortage. That window closed in December 2024 (tirzepatide) and February 2025 (semaglutide). Compounding now requires patient-specific clinical documentation or a 503B outsourcing route. Expect real adoption to lag projected adoption in counties with tight commercial coverage.
Decision path
Can patients access GLP-1 care in Fergus County?
Fergus County's projection is useful because it shows likely demand, but the practical decision still comes down to provider access, coverage, clinical fit, and pharmacy source.
- County
- Fergus
- State
- Montana
- Est. users
- 489
- Rank
- #43 of 56
Step 1
Read the local demand signal
Fergus County is 0.0 points below the Montana average, which can affect appointment availability and local pricing.
Compare MontanaStep 2
Check personal fit
The right next step depends on BMI, medical history, current medications, side-effect risk, and whether labs or in-person care are needed.
Check BMI criteriaStep 3
Verify the fill path
Before paying, confirm who prescribes, which pharmacy fills the medication, and how follow-up is handled after dose changes.
Review pharmacy checksEvidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
CDC PLACES
DatasetUsed for county-level obesity inputs in local GLP-1 adoption estimates.
KFF GLP-1 utilization polling
DatasetUsed as the national anchor for estimated GLP-1 adoption.
STEP 1 semaglutide obesity trial
TrialPrimary trial source for semaglutide 2.4 mg weight-loss expectations and side effects.
Frequently asked questions
How did you estimate GLP-1 users in Fergus County?
What's the difference between projected and real usage?
Do GLP-1 medications work the same for everyone?
Are there side effects I should know about?
Can I get GLP-1 care locally in Fergus County?
Sources and methodology
- Population: US Census Bureau, ACS 5-year estimates (2022).
- CDC PLACES county-level obesity estimates, 2023 release
- KFF Health Tracking Poll 2024: one in eight US adults has taken a GLP-1
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216.
- Adoption formula: county % = k x county obesity %, where k = 0.1361 (5.7% / 41.9%). Users = population x county %.
Related reading
glp1
Compounded Semaglutide Guide
How compounded semaglutide access works, what to ask a pharmacy, and how to compare safety and pricing.
glp1
Semaglutide Cost Comparison
Compare semaglutide pricing across brand, insurance, cash-pay, and compounded access paths.
experience
Tirzepatide Side Effects Complete Guide
Common tirzepatide side effects, warning signs, and practical management steps to discuss with a clinician.
glp1
Semaglutide Injection Sites
How to rotate semaglutide injection sites and reduce irritation, bruising, and technique problems.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Considering a GLP-1 in Fergus County?
A 2-minute FormBlends assessment, reviewed by a clinician licensed in Montana. Ships in 48 hours.
Start your assessmentAdoption rates on this page are modeled projections, not measured prescription counts. Content is information only, not medical advice. Talk to a licensed clinician before starting any medication. Individual results vary.